New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT07304128
Summary
This is the first human study of an experimental drug called PLB-002 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and understand how the drug behaves in the body. The study will enroll about 100 participants with specific tumor types, including ovarian, lung, and testicular cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center- Gynecology Onc
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Email: •••••@•••••
-
Fudan University Shanghai Cancer Center- Phase 1
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.